Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27283860

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Jul
First author
Planchard D

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):860-862. doi: 10.1016/S1470-2045(16)30203-0.
    note
    Source null
    related pmid
    27283865
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2016 Sep;8(9):2369-2371. doi: 10.21037/jtd.2016.09.16.
    note
    Source null
    related pmid
    27746978
    relationship
    Comment in

Authors and identifiers

  1. name
    Planchard D
    type
    Author
  2. name
    Besse B
    type
    Author
  3. name
    Groen HJM
    type
    Author
  4. name
    Souquet PJ
    type
    Author
  5. name
    Quoix E
    type
    Author
  6. name
    Baik CS
    type
    Author
  7. name
    Barlesi F
    type
    Author
  8. name
    Kim TM
    type
    Author
  9. name
    Mazieres J
    type
    Author
  10. name
    Novello S
    type
    Author
  11. name
    Rigas JR
    type
    Author
  12. name
    Upalawanna A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Planchard D
    type
    Author
  2. name
    Besse B
    type
    Author
  3. name
    Groen HJM
    type
    Author
  4. name
    Souquet PJ
    type
    Author
  5. name
    Quoix E
    type
    Author
  6. name
    Baik CS
    type
    Author
  7. name
    Barlesi F
    type
    Author
  8. name
    Kim TM
    type
    Author
  9. name
    Mazieres J
    type
    Author
  10. name
    Novello S
    type
    Author
  11. name
    Rigas JR
    type
    Author
  12. name
    Upalawanna A
    type
    Author
bibliography ids
  1. nci-bib-79535e5bd206a1e8fa7aeeb4
book metadata
content sha256
2d2f761f3822d92cff663b96bc82024818052d132420c223061bc6eda7c3844f
document type
citation
dois
  1. 10.1016/S1470-2045(16)30146-2
electronic publication date
display
2016 Jun 6
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27283860
immutable id
pubmed:27283860@2d2f761f3822d92cff663b96bc82024818052d132420c223061bc6eda7c3844f
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
984-993
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Jul;17(7):860-862. doi: 10.1016/S1470-2045(16)30203-0.
    note
    Source null
    related pmid
    27283865
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2016 Sep;8(9):2369-2371. doi: 10.21037/jtd.2016.09.16.
    note
    Source null
    related pmid
    27746978
    relationship
    Comment in
outcomes validated
false
pmid
27283860
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
6fb4a6a2ded32761204f0f49a53acf12cad46b85e36aebd39b33993d2729b998
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Jul
precision
month
year
2016
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27283860/
title
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Preserved source evidence · Not medical advice